Overview
Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
Status:
Completed
Completed
Trial end date:
2019-06-07
2019-06-07
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this first in human study is to assess safety, tolerability, PK and preliminary clinical activity and to estimate the MTD(s)/RDE(s) of MIK665 (also referred as S64315) as single agent administered intravenously (i.v.) in adult patients with refractory or relapsed lymphoma or multiple myeloma.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion Criteria- Age ≥ 18 years.
- Histologically confirmed lymphoma (WHO classification), or confirmed MM (IMWG), that
is relapsed and/or refractory.
- Other Inclusion Criteria May Apply.
Exclusion Criteria
- Known history of chronic liver disease
- History of chronic pancreatitis.
- Prior treatment with Mcl-1 inhibitor.
- Other Exclusion Criteria May Apply.